Issue link: https://www.e-digitaleditions.com/i/1499694
4 BioPharm International ® Partnerships for Outsourcing eBook May 2023 www.biopharminternational.com T he pharmaceutical outsourcing market is uniquely poised for significant growth. A re- cent market report from Growth+ Markets es- timated that the market could grow from a 2021 valuation of $125 billion to as much as $227.8 billion by 2030, with an estimated compound annual growth rate of 6.9% (1). That said, simply measuring net growth lacks the context for actionable information if one fails to iden- tify the market segments that are driving said growth. One effective way of identifying these growth drivers is to look to the major players in the pharma market. By following the moves of pharma giants, upcoming trends can be identified ahead of their full emergence in the broader outsourcing market. This article exam- ines some recent moves made by big name companies to determine what may be lurking over the horizon. Doubling down on biologics Post-COVID, the pharmaceutical industry has seen a boom in interest surrounding biologics, and more specifically messenger RNA (mRNA) therapeutics. Correspondingly, companies have made crucial moves to invest in the field; Lonza, for instance, announced a major collaboration with Touchlight, a biotechnology company specializing in enzymatic DNA production, in September 2022. The goal of this collaboration, ac- cording to a company press release, was to use linear, covalently closed DNA vectors as a differentiated source of DNA in its mRNA therapeutics and vaccines (2). Many other companies have pursued similar mRNA-oriented collaborations; in 2023 alone, AbbVie and Moderna have made big deals with companies specializing in this field, with collaborations valued at $582 million and $1.24 billion, respectively (3,4). This, in turn, has led to an increase in demand for the tools associated with mRNA therapeutic production. For instance, Lonza also struck a deal with Singzyme, a company specializing in developing enzymes for pro- tein ligation, in November 2022 to acquire their bio- conjugation tools for use in biologics (5). Similarly, lipid Identifying Outsourcing Market Trends Grant Playter, associate editor Outsourcing collaborations provide insight into the key drivers of market growth. YINGYAIPUMI - STOCK.ADOBE.COM